HRS9531 Injection for obesity

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 4 registered trials.

Why this status

  1. 2 May 2024: Trial registered, NCT06396429
  2. 13 May 2024: Trial started, NCT06396429
  3. 16 Dec 2025: Trial registered, NCT07285902
  4. 25 Dec 2025: Trial started, NCT07285902

The trials

NCT05881837: A Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes

State
Completed
Phase
Phase 2
People
249 taking part
Started
13 Jun 2023
Primary completion
13 Oct 2024
Arms
Treatment group A, Treatment group B, Treatment group C, Treatment group D
Results
None posted
  1. 31 May 2023: Trial registered
  2. 13 Jun 2023: Trial started
  3. 13 Oct 2024: Trial completed

NCT06054698: Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects

State
Completed
Phase
Phase 2
People
61 taking part
Started
16 Oct 2023
Primary completion
9 Sep 2024
Arms
HRS9531 injection
Results
None posted
  1. 26 Sep 2023: Trial registered
  2. 16 Oct 2023: Trial started
  3. 9 Sep 2024: Trial completed

NCT06396429: To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese

State
Completed
Phase
Phase 3
People
567 taking part
Started
13 May 2024
Primary completion
7 Jul 2025
Arms
Treatment group A: HRS9531 injection, Treatment group B: HRS9531 injection, Treatment group C: HRS9531 injection
Results
None posted
  1. 2 May 2024: Trial registered
  2. 13 May 2024: Trial started
  3. 7 Jul 2025: Trial completed

NCT07285902: A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity

State
Under way
Phase
Phase 3
People
572 taking part
Started
25 Dec 2025
Primary completion
Mar 2027
Arms
Treatment group A: HRS9531 injection
Results
None posted
  1. 16 Dec 2025: Trial registered
  2. 25 Dec 2025: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.